WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 564413
Description: JMS-053 is a potent inhibitor of the dual specificity phosphatase PTP4A3 that is potentially suitable for cancer therapy. JMS-053 markedly enhanced microvascular barrier function after exposure of endothelial cells to vascular endothelial growth factor or lipopolysaccharide. JMS-053 also blocked the concomitant increase in RhoA activation and loss of Rac1. In human ovarian cancer cells, JMS-053 impeded migration, disrupted spheroid growth, and decreased RhoA activity. Importantly, JMS-053 displayed anticancer activity in a murine xenograft model of drug resistant human ovarian cancer.
MedKoo Cat#: 564413
Chemical Formula: C13H8N2O2S
Exact Mass: 256.0306
Molecular Weight: 256.28
Elemental Analysis: C, 60.93; H, 3.15; N, 10.93; O, 12.49; S, 12.51
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: JMS-631-053; JMS053; JMS 053; JMS-053
IUPAC/Chemical Name: 7-Imino-2-phenylthieno[3,2-c]pyridine-4,6(5H,7H)-dione
InChi Key: CQHAROORCYWRRH-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H8N2O2S/c14-10-11-8(12(16)15-13(10)17)6-9(18-11)7-4-2-1-3-5-7/h1-6,14H,(H,15,16,17)
SMILES Code: O=C1C(C=C(C2=CC=CC=C2)S3)=C3C(C(N1)=O)=N
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 256.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Lazo JS, Sharlow ER, Cornelison R, Hart DJ, Llaneza DC, Mendelson AJ, Rastelli EJ, Tasker NR, Landen CN Jr, Wipf P. Credentialing and Pharmacologically Targeting PTP4A3 Phosphatase as a Molecular Target for Ovarian Cancer. Biomolecules. 2021 Jun 30;11(7):969. doi: 10.3390/biom11070969. PMID: 34209460; PMCID: PMC8329922.
2: Rastelli EJ, Sannino S, Hart DJ, Sharlow ER, Lazo JS, Brodsky JL, Wipf P. Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway. Bioorg Med Chem Lett. 2021 Aug 15;46:128167. doi: 10.1016/j.bmcl.2021.128167. Epub 2021 Jun 2. PMID: 34089839.
3: Czub MP, Boulton AM, Rastelli EJ, Tasker NR, Maskrey TS, Blanco IK, McQueeney KE, Bushweller JH, Minor W, Wipf P, Sharlow ER, Lazo JS. Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human Serum Albumin. Mol Pharmacol. 2020 Dec;98(6):648-657. doi: 10.1124/molpharm.120.000131. Epub 2020 Sep 25. Erratum in: Mol Pharmacol. 2020 Dec;98(6):781. PMID: 32978326; PMCID: PMC7658597.
4: Aguilar-Sopeña O, Hernández-Pérez S, Alegre-Gómez S, Castro-Sánchez P, Iglesias-Ceacero A, Lazo JS, Roda-Navarro P. Effect of Pharmacological Inhibition of the Catalytic Activity of Phosphatases of Regenerating Liver in Early T Cell Receptor Signaling Dynamics and IL-2 Production. Int J Mol Sci. 2020 Apr 5;21(7):2530. doi: 10.3390/ijms21072530. PMID: 32260565; PMCID: PMC7177812.
5: Lazo JS, Blanco IK, Tasker NR, Rastelli EJ, Burnett JC, Garrott SR, Hart DJ, McCloud RL, Hsu KL, Wipf P, Sharlow ER. Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase. J Pharmacol Exp Ther. 2019 Dec;371(3):652-662. doi: 10.1124/jpet.119.262188. Epub 2019 Oct 10. PMID: 31601683; PMCID: PMC6856870.
6: McQueeney KE, Salamoun JM, Ahn JG, Pekic P, Blanco IK, Struckman HL, Sharlow ER, Wipf P, Lazo JS. A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion. FASEB J. 2018 Oct;32(10):5661-5673. doi: 10.1096/fj.201701446R. Epub 2018 May 10. PMID: 29746167; PMCID: PMC6133700.
7: McQueeney KE, Salamoun JM, Burnett JC, Barabutis N, Pekic P, Lewandowski SL, Llaneza DC, Cornelison R, Bai Y, Zhang ZY, Catravas JD, Landen CN, Wipf P, Lazo JS, Sharlow ER. Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor. Oncotarget. 2017 Dec 30;9(9):8223-8240. doi: 10.18632/oncotarget.23787. PMID: 29492190; PMCID: PMC5823565.